Pharmaceuticals

Global Nuclear Medicine Radioisotopes Market Size Projected to Reach $11.96 Billion During the Forecast Period

November 10, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

By How Much Is The Nuclear Medicine Radioisotopes Market Expected To Expand Between 2025 And 2029?

The nuclear medicine radioisotopes market has observed significant expansion in recent times. Its valuation is expected to rise from $8.21 billion in 2024 to $8.85 billion in 2025, reflecting a compound annual growth rate (CAGR) of 7.9%. Historically, the market’s expansion was fueled by factors such as the initial discovery of radioactivity, the development of nuclear medicine, diverse therapeutic applications, ongoing clinical research, and increasing patient requirements.

The nuclear medicine radioisotopes market is projected to experience substantial expansion over the upcoming years. This market is anticipated to reach “$11.96 billion in 2029, demonstrating a compound annual growth rate (CAGR) of 7.8%.” This anticipated growth during the forecast period can be ascribed to several factors, including heightened healthcare expenditures, the broadening of healthcare infrastructure, increasing consciousness regarding environmental sustainability, various educational campaigns and awareness initiatives, and the rise in medical tourism. Key trends foreseen in this period encompass the creation of novel radioisotopes, advancements in production and supply chain methodologies, the application of microfluidics and lab-on-a-chip technology, the integration of artificial intelligence into radiopharmaceutical development, and the utilization of nanotechnology.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16132&type=smp

Which Drivers Are Impacting The Nuclear Medicine Radioisotopes Market?

An increase in cardiovascular disease incidence is projected to drive the expansion of the nuclear medicine radioisotope market in the future. These conditions encompass various ailments impacting the heart and vascular system. The growing prevalence of cardiovascular illnesses stems from inactive lifestyles, unhealthy eating patterns, escalating obesity rates, and an aging demographic. Nuclear medicine radioisotopes offer crucial support in the diagnosis, assessment, and treatment of cardiovascular conditions, providing specific details on heart function, blood flow, and tissue health, all vital for precise diagnosis and successful therapeutic strategies. For example, data released by the British Heart Foundation, a UK cardiovascular research charity, in September 2024, indicates that approximately 7.6 million individuals in the UK suffer from heart and circulatory diseases, comprising about 4 million males and 3.6 million females. These ailments account for around 27% of all fatalities in the UK, leading to more than 170,000 deaths each year, which averages out to approximately 480 deaths daily, or one death every three minutes. Consequently, the increasing incidence of cardiovascular diseases is propelling the expansion of the nuclear medicine radioisotope market.

What Are The Major Segments Identified In The Nuclear Medicine Radioisotopes Market?

The nuclear medicine radioisotopes market covered in this report is segmented –

1) By Type: Technetium-99m (Tc-99m), Thallium-201 (Tl-201), Iodine (I-123), Fluorine-18, Rubidium-82 (Rb-82), Iodine-131 (I-131), Lutetium-177 (Lu-177), Radium-223 (Ra-223) And Alpharadin, Other Types

2) By Application: Oncology, Cardiology, Thyroid, Neurology, Other Applications

3) By End-User: Hospitals, Diagnostic Centers, Specialty Clinics, Education And Research Institutes, Other End-Users

Subsegments:

1) By Technetium-99m (Tc-99m): Sodium Pertechnetate Tc-99m, Tc-99m MDP (Methylene Diphosphonate), Tc-99m HMPAO (Hexamethylpropyleneamine oxime)

2) By Thallium-201 (Tl-201): Thallous Chloride Tl-201, Thallium-201 for Cardiac Imaging

3) By Iodine-123 (I-123): Iodine-123 Sodium Iodide, Iodine-123 Ioflupane (DaTscan)

4) By Fluorine-18: FDG (Fluorodeoxyglucose) F-18, Fluoride-18 For Bone Imaging

5) By Rubidium-82 (Rb-82): Rb-82 For PET (Positron Emission Tomography) Imaging, Rb-82 For Cardiac Imaging

6) By Iodine-131 (I-131): I-131 Sodium Iodide, I-131 For Thyroid Cancer Treatment, I-131 For Hyperthyroidism Treatment

7) By Lutetium-177 (Lu-177): Lu-177-DOTATATE, Lu-177 For Prostate Cancer Treatment

8) By Radium-223 (Ra-223): Ra-223 Dichloride (Xofigo)

9) By Alpharadin (Radium-223 Alpha Emitters): Alpharadin For Bone Metastasis Treatment

10) By Other Types: Ac-225 For Targeted Alpha Therapy (TAT), Ac-225 For Cancer Treatment, Gallium-68 (Ga-68), Copper-64 (Cu-64), Yttrium-90 (Y-90)

What Are The Latest Industry Trends Transforming The Nuclear Medicine Radioisotopes Market?

Leading companies in the nuclear medicine radioisotopes market are concentrating on creating advanced products, such as the compact low-energy cyclotron, to boost the production and availability of radioisotopes. This effort aims to provide more efficient and accessible options for diagnosis and therapy. A compact, low-energy cyclotron is a small particle accelerator utilized to generate radioisotopes for medical imaging and treatments within nuclear medicine. For instance, in January 2022, IBA, a Belgium-based provider of radiopharmaceutical production solutions, introduced Cyclone Key. This new accelerator enhances access to diagnostic solutions and allows for the in-house production of radiopharmaceuticals. This inventive solution features a compact and efficient design, fully automated operation, capabilities for producing multiple isotopes, simple installation and operation, water cooling, self-shielding, and high performance, thus making it versatile and reliable.

Which Key Players Are Driving Competition In The Nuclear Medicine Radioisotopes Market?

Major companies operating in the nuclear medicine radioisotopes market are Cardinal Health Inc., Bayer AG, Siemens Healthineers AG, GE HealthCare Technologies, BWX Technologies Inc., Mallinckrodt Pharmaceuticals, Bracco Imaging S.p.A., Lantheus Holdings Inc., Curium Pharma, Australian Nuclear Science and Technology Organisation (ANSTO) Health, Eckert & Ziegler Strahlen, NorthStar Medical Radioisotopes, NTP Radioisotopes, Shine Medical Technologies Inc., Jubilant DraxImage Inc., Isotopia Molecular Imaging Ltd., Eczacibasi-Monrol Nuclear Products, International Isotopes Inc., Polatom Sp. z o.o., Radiomedix Inc., Positron Corporation

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/nuclear-medicine-radioisotopes-global-market-report

Which Region Currently Holds The Largest Share Of The Nuclear Medicine Radioisotopes Market?

North America was the largest region in the nuclear medicine radioisotopes market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nuclear medicine radioisotopes market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Nuclear Medicine Radioisotopes Market Report:

https://www.thebusinessresearchcompany.com/customise?id=16132&type=smp

Browse Through More Reports Similar to the Global Nuclear Medicine Radioisotopes Market 2025, By The Business Research Company

Nuclear Imaging Devices And Equipment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/nuclear-imaging-devices-and-equipment-global-market-report

Nuclear Electricity Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/nuclear-electricity-global-market-report

Nuclear Power Reactor Decommissioning Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/nuclear-power-reactor-decommissioning-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795